Molecular Insight Pharmaceuticals to Present at Lazard Capital Markets Annual Healthcare Conference
More News related to MIPI
- Molecular Insight Pharmaceuticals Announces Changes to Board
- Molecular Insight Pharmaceuticals to Present at Lazard Capital Markets Annual Healthcare Conference
- Molecular Insight Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Molecular Insight Pharmaceuticals, Inc. to Report Third Quarter Financial Results on November 9, 2009
- Molecular Insight Pharma (MIPI) Executes 10-Year Agreement to Supply Onalta to BioMedica Life Sciences
More News related to Press Releases
- Research and Markets: Economic Downturn and Stringent Environmental Laws Boost the Web Conferencing Services Market in Europe
- Electrovaya Presenting at the Dundee Investor's Conference and Advanced Battery Value Chain Summit
- Research and Markets: Dreamforce 2009: Salesforce Targets the Entire Enterprise
- Search Engine Strategies Announces Dates For The 2010 London SES Conference & Expo
- Downsview Park's Trail of Lights Colours the Sky This Holiday Season!
CAMBRIDGE, MA -- (MARKET WIRE) -- 11/11/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), announced that John W. Babich, Ph.D., Executive Vice President, Chief Scientific Officer and President of Research and Development, will present an overview of the Company and its pipeline of targeted therapeutic oncology radiopharmaceuticals at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009 at 3:15 PM, Eastern Standard Time. The presentation will take place at the St. Regis Hotel in New York, New York.
The presentation will be webcast live at http://www.wsw.com/webcast/lz6/mipi/ and it will be archived for 90 days. The webcast also will be available in the Investor Relations section of the Molecular Insight Pharmaceuticals website at www.molecularinsight.com.
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and pioneer in the emerging field of molecular medicine. The Company is focused on the discovery and development of targeted therapeutic and imaging radiopharmaceuticals, primarily for use in oncology. Molecular Insight has five clinical-stage candidates in development. For further information on Molecular Insight Pharmaceuticals, please visit www.molecularinsight.com.
Contact: Investors Chuck Abdalian Chief Financial Officer (617) 871-6618 cabdalian@molecularinsight.com Media Martin A. Reynolds Manager Corporate Communications (617) 871-6734 mreynolds@molecularinsight.com Susan Pietropaolo BCC Partners (845) 638-6290 (201) 923-2049 spietropaolo@bccpartners.com
Related Categories
Press ReleasesStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
